Talphera TLPH
NASDAQ TLPH
$1.24 +0.02 (+1.64%)
At close: Sep 10, 2026 · 4:00 PM EDT

Talphera (TLPH) Cash from Financing Activities (2010 - 2026)

Talphera (TLPH) posted Cash from Financing Activities of -$261000.0 for Q2 2026, down 106.46% on a QoQ basis from $4.0 million in Q1 2026, and down 106.0% year-over-year from $4.4 million in Q2 2025.

Analysis

Talphera (TLPH) Cash from Financing Activities (2010 - 2026) Analysis & Trends

Talphera has reported Cash from Financing Activities for 17 years, with the latest figure at -$261000.0 in Q2 2026.

  • On a quarterly basis, Cash from Financing Activities fell 106.0% year-over-year to -$261000.0 in Q2 2026; TTM through Jun 2026 was $22.2 million, a 406.76% increase from a year earlier, with the FY2025 full-year figure at $22.7 million, up 88.81% from the prior year.
  • Cash from Financing Activities was -$261000.0 for Q2 2026 at Talphera, down from $4.0 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $17.0 million in Q3 2025, with the low at -$3.3 million in Q2 2023.
  • Average Cash from Financing Activities over 5 years is $2.6 million, with a median of $12500.0 recorded in 2024.
  • The sharpest annual moves came in 2022 and 2026: Cash from Financing Activities tumbled 106.09% in 2022, then jumped 80960.0% in 2026.
  • Over 5 years, Cash from Financing Activities stood at $5.3 million in 2022, then slumped by 101.28% to -$68000.0 in 2023, then jumped by 144.12% to $30000.0 in 2024, then surged by 4576.67% to $1.4 million in 2025, then plunged by 118.6% to -$261000.0 in 2026.
  • The last three Cash from Financing Activities figures came in at -$261000.0 (Q2 2026), $4.0 million (Q1 2026), and $1.4 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn -1.48 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 2.34 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn -426.70 Mn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn -1.22 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn -
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn 14.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn 36.24 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 1.30 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn -181.51 Mn
10 Talphera 92.90 Mn 92.90 Mn - -261,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -261,000.00
Mar 31, 2026 4.04 Mn
Dec 31, 2025 1.40 Mn
Sep 30, 2025 16.99 Mn
Jun 30, 2025 4.35 Mn
Mar 31, 2025 -5,000.00
Sep 30, 2024 30,000.00
Mar 31, 2024 12.01 Mn
Dec 31, 2023 -68,000.00
Sep 30, 2023 8.94 Mn
Jun 30, 2023 -3.33 Mn
Mar 31, 2023 -2.07 Mn
Dec 31, 2022 5.30 Mn
Sep 30, 2022 -1.64 Mn
Jun 30, 2022 -2.08 Mn
Mar 31, 2022 -2.08 Mn
Dec 31, 2021 11.84 Mn
Sep 30, 2021 -2.46 Mn
Jun 30, 2021 -2.08 Mn
Mar 31, 2021 34.22 Mn